Aiko Komatsu
Saga University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Aiko Komatsu.
Atherosclerosis | 2012
Aya Shiraki; Jun-ichi Oyama; Hiroshi Komoda; Machiko Asaka; Aiko Komatsu; Masashi Sakuma; Kazuhisa Kodama; Yoshiko Sakamoto; Norihiko Kotooka; Tetsuaki Hirase; Koichi Node
OBJECTIVE Glucagon-like peptide 1 (GLP-1), one of the incretin hormones, has been reported to increase positive inotropic activity in cardiac myocytes and protect against myocardial injury. However, the effects upon endothelial cells and the mechanisms involved are not fully understood. We assessed the hypothesis that GLP-1 has protective effects against inflammation and oxidative stress on human endothelial cells. METHODS AND RESULTS The effects of the GLP-1 analog liraglutide upon TNF-α-induced injury of the human umbilical vein endothelial cells (HUVECs) were evaluated. First, ROS induced by TNF-α was measured by staining with CM-H(2)DCFDA. Intracellular ROS production of HUVECs was significantly decreased in a dose-dependent manner until 30 nM while liraglutide inhibited the induction of gp91(phox) and p22(phox), subunit of NADPH oxidase, by TNF-α. In addition, protein levels of SOD-2, catalase and GPx were significantly increased by liraglutide. Second, rapid translocation of PKC-α into the membrane following TNF-α was evident. Liraglutide significantly inhibited this very rapid TNF-α-induced translocation of PKC-α into membrane at 2.5 min. Third, liraglutide significantly inhibited NF-κB activation and upregulated I-κB family while phosphorylation of IKK-α/β, which is upstream of NF-κB signaling, was also downregulated after 15 min of TNF-α treatment. Finally, liraglutide inhibited apoptosis of HUVEC and expression of Pentraxin-3 induced by TNF-α. CONCLUSION Liraglutide exerts marked anti-oxidative and anti-inflammatory effects on endothelial cells with inhibition of PKC-α, NADPH oxidase, NF-κB signaling and upregulation of protective anti-oxidative enzymes.
Cardiovascular Diabetology | 2014
Ikuko Nakamura; Jun-ichi Oyama; Hiroshi Komoda; Aya Shiraki; Yoshiko Sakamoto; Isao Taguchi; Atsushi Hiwatashi; Aiko Komatsu; Masayoshi Takeuchi; Sho-ichi Yamagishi; Teruo Inoue; Koichi Node
BackgroundThe purpose of this study was to elucidate the effects of glimepiride on the levels of biomarkers related to cardiovascular regulation in patients with type 2 diabetes mellitus.Methods and resultsThirty-four patients with type 2 diabetes received glimepiride for 24 weeks. Significant decreases in the levels of glyceraldehyde-derived advanced glycation end products, (glycer-AGE: toxic AGE), eotaxin and fibroblast growth factor (FGF)-2 were recognized after the administration of glimepiride. Moreover, there were trends for there to be increases in the levels of granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF), and decreases in the levels of fractalkine, soluble CD40 ligand (sCD40L), macrophage inflammatory protein (MIP)-β, vascular endothelial growth factor (VEGF) and soluble receptor for AGE (sRAGE).ConclusionsGlimepiride may have potent anti-oxidative, anti-inflammatory and angiogenic properties and it may potentially repair tissue damage by decreasing the levels of toxic AGE and increasing colony-stimulating factors.
The Cardiology | 2006
Toshifumi Morooka; Teruo Inoue; Norihiko Kotooka; Daisuke Fujimatsu; Aiko Komatsu; Fumi Uchida; Kazuyo Yoshida; Shigemasa Hashimoto; Yutaka Hikichi; Toru Kato; Koichi Node
Backgrounds: Although long-term treatment with beta-blockers has been shown to improve morbidity and mortality in dilated cardiomyopathy (DCM), patient re- sponses are heterogeneous. Methods: To establish the appropriate indication for the initiation of beta-blocker therapy, we retrospectively analyzed 38 DCM patients treated with beta-blockers (metoprolol or carvedilol) and examined differences in baseline profiles between patients who could continue the therapy (responders) and those who could not (non-responders). Results: In 13 non-responders, the duration from onset of symptoms to beta-blocker initiation was longer (p < 0.05), systolic blood pressure was lower (p < 0.001), serum sodium concentration was lower (p < 0.05), left ventricular posterior wall thickness was thinner (p < 0.05), left ventricular end-diastolic pressure was higher (p < 0.05) and left ventricular wall stress was lower (p < 0.05) than in 25 responders. In 19 patients receiving carvedilol, 5 non-responders showed higher levels of human atrial natriuretic peptide (p < 0.05) and brain natriuretic peptide (p < 0.01) than 13 responders. Discriminant analysis with a linear discriminant function showed the following equation predicted response to beta-blocker therapy: h = 0.004 × systolic blood pressure – 0.002 × brain natriuretic peptide + 0.667 (R2 = 0.67, p < 0.001). The probability of predicting the response was 94.1% with h ≧0.5. Conclusion: We conclude that h≧0.5 is the appropriate indication for the initiation of beta-blocker therapy in DCM.
Heart and Vessels | 2016
Mitsuhiro Shimomura; Jun-ichi Oyama; Masayoshi Takeuchi; Yoshisato Shibata; Yusuke Yamamoto; Tomohiro Kawasaki; Hiroshi Komoda; Kazuhisa Kodama; Masashi Sakuma; Shigeru Toyoda; Yohei Inoue; Daigo Mine; Masahiro Natsuaki; Aiko Komatsu; Yutaka Hikichi; Sho-ichi Yamagishi; Teruo Inoue; Koichi Node
International Journal of Cardiology | 2013
Norihiko Kotooka; Aiko Komatsu; Hiro Takahashi; Masako Nonaka; Chiharu Kawaguchi; Hiroshi Komoda; Machiko Asaka; Shichiro Abe; Isao Taguchi; Shigeru Toyoda; Masanori Nishiyama; Teruo Inoue; Koichi Node
Archive | 2011
Hiroaki Kawano; Yasuhiro Nagayoshi; Sunao Kojima; Nahoko Kakihara; Satoshi Sakuma; Masumi Uchino; Aiko Komatsu; Machiko Asaka; Mitsuhiro Shimomura; Hiroshige Yamabe; Hisao Ogawa; Koichi Node
International Journal of Physical Medicine and Rehabilitation | 2011
Hiroaki Kawano; Yasuhiro Nagayoshi; Sunao Kojima; Nahoko Kakihara; Satoshi Sakuma; Masumi Uchino; Aiko Komatsu; Machiko Asaka; Mitsuhiro Shimomura; Hiroshige Yamabe; Hisao Ogawa; Koichi Node
Japanese Circulation Journal-english Edition | 2009
Aiko Komatsu; Tetsuaki Hirase; Machiko Asaka; Koichi Node
Circulation | 2009
Aiko Komatsu; Tetsuaki Hirase; Machiko Asaka; Koichi Node
Japanese Circulation Journal-english Edition | 2006
Koichi Node; Teruo Inoue; Yutaka Hikichi; Daisuke Fujimatsu; Aiko Komatsu; Mitsuhiro Shimomura; Yoshisato Shibata; Tomohiro Kawasaki; Aoi Kamura; Yusuke Yamamoto